#Endocrine Testing Market

[marketsndata]

Global Endocrine Testing Market Size, Share, Growth and Forecast 2031

Global endocrine testing market is projected to witness a CAGR of 8.17% during the forecast period 2024-2031, growing from USD 13.03 billion in 2023 to USD 24.42 billion in 2031. The market’s growth is supported by the rising incidences of endocrine disorders, increasing awareness about preventive healthcare, and growing product launches by market players with enhanced features and patient convenience. In August 2023, the US Food and Drug Administration (FDA) listed the Mira Fertility Ovum Wand as an over-the-counter tool for tracking follicle-stimulating hormone (FSH) levels in urine. The wand can provide lab-accurate FSH levels for assessing fertility, predicting menopause, and supporting ovulation predictions.

Endocrine testing is essential for identifying abnormalities and imbalances in the endocrine system and assessing hormone levels for management and early detection of health conditions such as reproductive issues, diabetes, and thyroid disorders. Increasing investments by the healthcare sector to bolster the accessibility and affordability of these tests are expected to influence the market’s expansion positively.

Furthermore, the rising awareness among the general population about endocrine disorders and the increasing efforts by various healthcare organizations to boost the accessibility of endocrine testing are providing lucrative growth opportunities to the market. Several healthcare organizations and government institutions are increasingly focusing on regular checkups for population groups that are at a higher risk of developing diabetes and thyroid disorders. Meanwhile, the general population is seeking regular health checkups to identify potential health issues on time due to increasing health consciousness. Additionally, the shift towards preventive healthcare is also propelling the demand for endocrine testing in various regions across the globe.

Increasing Prevalence of Endocrine Disorders Boosts Market Demand

Factors such as environmental influence, lifestyle changes, and genetic predisposition contribute significantly to endocrine disorders. These disorders also occur if the body cannot respond to hormones as it is supposed to. According to a National Center for Biotechnology Information (NCBI) study, the prevalence of endocrine disorders in adults in the United States is at least 5%. The rising cases of endocrine disorders are thus bolstering the reliance on endocrine testing to detect hormonal abnormalities and identify diseases.

The increasing incidences of hypothyroidism and diabetes, coupled with the increasing awareness about such conditions, is another major factor boosting the global endocrine testing market size.

Additionally, environmental factors and evolving lifestyles are also propelling the prevalence of endocrine disorders. Rising exposure to endocrine-disrupting chemicals, poor diet, stress, and sedentary habits have also been linked with the growing incidences of endocrine diseases. Endocrine-disrupting chemicals are usually found in a wide range of products, from pesticides to plastics, and have been shown to interfere with optimal hormone functioning, resulting in conditions such as reproductive health issues and thyroid imbalance.

Development of Novel Technologies Supports Market Expansion

The development of novel products and technologies plays a vital role in expanding the global endocrine testing market. Advancements in monitoring and diagnostics allow the development of endocrine testing solutions that deliver more reliable and faster results, allowing healthcare professionals to diagnose complex hormonal issues effectively. The growing demand for efficient, accessible, and patient-friendly testing solutions is thus propelling the growth of the endocrine testing market. Healthcare companies and startups across the globe are actively working on launching newer endocrine testing devices.

In July 2023, Mylab Discovery Solutions Pvt. Ltd., a Pune-based biotech startup, launched the Mybox+ diagnostic device with a broad range of tests, including biomarker (CRP, D-Dimer), cardiac marker (Troponin), and thyroid panel (T-3, T-4, TSH). Introducing this solution and the Dry Luminescence technology shows a transformative step in diagnostics and empowers clinics and labs by allowing them to provide a wide range of tests, thus aiding them in improving patient care. This technology offers a game-changing solution for clinics and small laboratories that have previously faced limitations in performing various tests and had to rely on larger facilities, often resulting in increased costs and delayed results. Thus, developing novel technologies improves patient convenience and positively influences the expansion of the endocrine testing market. 

Thyroid Stimulating Hormone (TSH) Test Accounts for Significant Market Share

The growth of the segment is supported by increasing awareness about the importance of early detection of thyroid disorders and the rising prevalence of such conditions. According to the estimates of the American Thyroid Association, approximately 20 million Americans have some type of thyroid disease. Thyroid testing focuses on checking T3, T4, and TSH levels. It is one of the most performed endocrine tests across the globe as the incidences of hyperthyroidism and hypothyroidism increase. The growing efforts by the leading market players to ensure the availability of accurate and user-friendly testing devices and home-use testing kits are also expected to bolster the segment’s expansion and provide lucrative growth opportunities to the global endocrine testing market.

Additionally, the increasing integration of TSH tests in preventive healthcare practices, particularly in population groups that are at high risk or have a history of thyroid disorders, is also propelling the segment’s growth. Early detection can aid healthcare providers in preventing the occurrence of serious complications, including fertility issues, metabolic problems, and cardiovascular diseases. Furthermore, a rising number of healthcare professionals are advocating regular TSH testing for patients showing non-specific symptoms such as weight changes, fatigue, and depression, further bolstering the test’s demand.

North America Holds Major Market Share

The rapid expansion of the market in the region can be attributed to the expansion of the population, growth of the healthcare sector, introduction of proactive government measures and policies, increasing the burden of different diseases, and rising awareness among the patient population. The strong presence of leading market players and the easy availability of healthcare services are also positively influencing the market’s expansion.

The rising cases of endocrine-related diseases such as thyroid cancer are also bolstering the market demand in North America. According to the estimates of the American Cancer Society, approximately 44,020 new cases of thyroid cancer are expected to be reported in the United States in 2024. Additionally, the presence of various organizations that monitor and screen thyroid dysfunction and are devoted to thyroid biology and prevention and treatment of various thyroid diseases also provides lucrative growth opportunities to the market.

Furthermore, the rising cases of diabetes and the increasing requirement for insulin testing are also expected to bolster the market’s demand. As per the estimates of the Centers for Disease Control and Prevention, approximately 38 million individuals in the United States have diabetes.

Download Free Sample Report

Future Market Scenario (2024-2031F)

As per the global endocrine testing market analysis, the demand is expected to be driven by increasing emphasis on preventive healthcare, rapid advancements in diagnostic technologies, and increasing incidences of endocrine disorders. Additionally, the rising requirement for point-of-care testing and increasing integration of machine learning and artificial intelligence in diagnostics is expected to drive innovation and propel the global endocrine testing market growth. The increasing prevalence of various endocrine disorders, including thyroid disorders and diabetes, in combination with supportive reimbursement policies, is expected to drive the global endocrine testing market demand. As per the estimates by the International Diabetes Federation (IDF), approximately 783 million individuals across the globe will be living with diabetes by 2045.

Additionally, the rapid expansion of the population and increasing burden on the healthcare sector are also expected to provide lucrative growth opportunities for the market. Endocrine testing is usually deployed in cases where doctors suspect that the patient might have an endocrine disorder or receive abnormal results for other function studies. The blood tests aid in confirming or eliminating suspicions and allow the identification of the root cause of the problem. 

Report Scope

“Endocrine Testing Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global endocrine testing market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Click here for full report- https://www.marketsandata.com/industry-reports/endocrine-testing-market

Latest reports-

Contact

Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: info@marketsandata.com Website: https://www.marketsandata.com

[neha24blog]

Endocrine Testing Market Segmented On The Basis Of Test Type, Technology, End-User, Region And Forecast 2030: Grand View Research Inc.

San Francisco, 13 March 2023: The Report Endocrine Testing Market Size, Share & Trends Analysis Report By Test Type (hCG, FSH, TSH, Insulin), By Technology (Mass Spectroscopy, Immunoassay), By End-user, And Segment Forecasts, 2022 – 2030 The global endocrine testing market is expected to reach USD 4.79 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected…

[mitalipingale]

The Endocrine Peptides Test Market in 2023 is US$ 8.24 billion, and is expected to reach US$ 15.51 billion by 2031 at a CAGR of 8.22%.

[thescrumblingmidwife]

Are charcoal pads actually safe? They seem like the kind of thing to be revealed to be detrimental in like 40 years. My favorite brand just started using charcoal and I don’t know how to feel about it.

Hi Anon,

Not gonna lie, I had to do some digging for this one. I know putting charcoal in everything is very *in* right now, and it's usually unregulated and sometimes potentially problematic (for instance, don't ingest charcoal if you take any medications! It interferes with the absorption of medications). But I had never heard of charcoal pads, so thanks for bringing it to my attention.

MENSTRUAL PRODUCT SAFETY

Menstrual products are regulated by the FDA (Food and Drug Administration) as medical devices. The FDA does not require manufacturers to label ingredients, nor do they ban the use of known harmful products, and there is no safety standard that needs to be met. The labels "organic" and "all natural" are advertising and not statement of fact. Testing that has been done to check for harmful products has been done by watchdog agencies and independent researchers.

Here's a good rundown:

What is known is that a lot of menstrual products do contain harsh chemicals that are better avoided. Most fall below the threshold of increasing cancer and non-cancer health risks, but a few chemicals to be on the lookout for are benzene, n-heptane and 1,4-dioxane. (Lin et al., 2020), as these can increase cancer risk. Chlorine and other chemicals can cause irritation of the vuvla. Also problematic is the use of phthalates, which are endocrine disrupters (can mess with your hormones) (Gao et al., 2020). Another problem is polyfluoroalkyl substances (PFAS), or "forever chemicals," which show up in a lot of products, and never leave your body. The New York Times recently did a testing of 44 products to check for problematic chemicals, and they found that PFAS are present in most products in at least very small amounts, although the lowest levels were found in period underwear and medical-grade silicone inserts.

So, our starting point is that commercially available disposable pads and tampons are already something to be concerned about, because no one in any position of power is doing much to make sure they're safe. They touch mucous membranes, which means there is potential for significant absorption. We can talk in a minute about how to choose the safest products from what's out there.

But let's get back to charcoal!

The purported purpose of the charcoal is to cut down on "period odor," which is not something people around you can detect. This is a case of advertising convincing you there's a problem so they can sell you a solution. The company that manufactures these pads, Kimberly-Clark, does supply ingredient lists and their stated purpose on their website. (It's not clear if this is the entire ingredient list, but it's something.) Interestingly, the function of charcoal is listed only as "A colorant used to color a material." Nothing about odor absorption. The charcoal doesn't come into contact with the vulvar skin or vaginal mucosa, so I don't think the charcoal itself poses much of a risk. I suspect this is more a case of fad-based misleading advertising. Will they harm you? Probably not. Will they do something magical and new? Probably not.

The one upside may be that the use of charcoal in menstrual products reflects manufacturer's response to the market demanding products with more "natural" ingredients and fewer harsh chemicals. But this is something that should be tested.

Yikes, that was a lot.

SO WHAT'S SAFE?

It's important to note that none of the chemical levels in any of these products are so bad that you're going to get cancer from wearing a single pad. The most common risk is vulvar irritation from harsh chemicals. The scariest (but rarer) risk is cumulative exposure over a long period of time for a marginally increased risk of some health issues.

But here are some tips for picking the safest products for your body:

Use a medical-grade silicone insert/menstrual cup (like a Diva cup).

Use reusable period underwear or pads from a reputable brand, like Thinx, and wash them before you use them.

If using disposable pads or tampons, absolutely avoid any with fragrances.

Use the lowest possible absorbency you need - the higher the absorbency, the more the material has been treated.

Try using disposable incontinence pads instead of menstrual pads, as these had lower rates of PFAS and chemicals.

Although there's no way to guarantee it's truthful, try to stick to brands and products that are generally chlorine-free. cotton-based, etc.

If you experience any irritation, redness, or sensitivity, try a new product!

And for those charcoal pads - they don't strike me as being any worse for you than the rest of the Kotex's fragrance-free lineup. It's not as problematic as swallowing charcoal or rubbing the dentin off your teeth with it. You may be right that in 15 years we'll have realized this was like that time we were putting radium in everything, but I doubt it?

Sources:

Lin, N., Ding, N., Meza-Wilson, E., Manuradha Devasurendra, A., Godwin, C., Kyun Park, S., & Batterman, S. (2020). Volatile organic compounds in feminine hygiene products sold in the US market: A survey of products and health risks. Environment International, 144, 105740. https://doi.org/10.1016/j.envint.2020.105740

Gao, C. J., Wang, F., Shen, H. M., Kannan, K., & Guo, Y. (2020). Feminine hygiene products-A neglected source of phthalate exposure in women. Environmental Science & Technology, 54(2), 930–937. https://doi.org/10.1021/acs.est.9b03927

[kenresearchcompany]

Thailand Clinical Laboratory Industry Has Evolved Over the Years and Has Become a Critical Solution Provider: Ken Research

Buy Now

Expanding healthcare spending by the Government, increasing healthcare spending by aging population and increasing public awareness led to the growth of the Clinical Laboratory Market in Thailand.

Thailand Clinical Laboratory Market Overview: The Clinical Laboratory Market in Thailand is currently at the growth stage and is a consolidated market. The market has been driven by growth in non-communicable disease and chronic diseases, increasing focus on preventive medicine, ageing population, increase in awareness levels, rising disposable income and preference for evidence based treatment. The Thailand Clinical Laboratory Market grew from 6.7% in 2017 to 12.3% in 2021 in terms of revenue generated, due to the growing demand for clinical laboratory services in the country.

Challenges Faced by Thailand Clinical Laboratory Market: In spite of the growing demand for diagnostic services, affordability remains a concern. Budget constraints from both public and private payers are pushing costs lower. The number of sample sales and test price are very competitive among both organized and unorganized businesses. Diagnostics facilities need to modify their technology frequently to maintain a competitive edge. However, these improvements not only require large construction expenditures but also raise maintenance expenses. This is essential, especially for smaller players with little resources. Lack of laboratory accountability for the services that they render, insufficient oversight of suppliers, consumables, supplies, and laboratory equipment in terms of price, commitments, and warranty support; are still very challenging issues.

Supportive Government Initiatives: Thailand’s reform places a heavy emphasis on improving a district health system that is pro-rural and pro-poor. To promote lab accreditation and restore consumer trust, the government has established national accreditation bodies such as the Thailand Laboratory Accreditation Program. The national accreditation program was established as a local alternative to make it affordable, feasible, scalable, sustainable, and effective. In 2008, Thailand’s Universal Coverage Scheme (UCS) was extended to include wider coverage. The UCS plan focuses on minorities and the poor and near-poor, with the aim of offering the most comprehensive coverage possible. It includes extensive outpatient and inpatient health care, as well as prevention and health promotion, in addition to basic hospital fees.

Analysts at Ken Research in their latest publication “Thailand Clinical Laboratory Market Outlook to 2026F- Driven by current shortage, widening customer base, Government initiatives and increasing corporate requirements for clinical testing” by Ken Research observed that Thailand Clinical Laboratory Market is in the growing phase. Increasing healthcare spending by aging population, expanding healthcare spending by the Government and increasing public awareness are some of the factors that will contribute to the Thailand Clinical Laboratory Market growth over the period of 2022F-2026F. It is expected that Thailand Clinical Laboratory Market will grow at a CAGR of 9.5% for the above forecasted period.

Key Segments Covered

Thailand Clinical Laboratory Market:

By Independent Laboratory

Organized Labs

Unorganized Labs

By Payer

Private Health Insurance

Corporates

Out of Pocket

By Customers

Walk-Ins

Doctor Referrals

Corporate Clients

Online Bookings

Request for a Free Sample Report @ https://www.kenresearch.com/sample-report.php?Frmdetails=NTk2MjIz

By Type of Tests

Routine

Esoteric

Non-Laboratory

By Type of Routine Tests

CBC (Complete Blood Count)

A1C

Basic Metabolic Panel

Others

By Type of Esoteric Tests

Infectious Disease

Endocrine

Allergic Disease

Oncology

Others

By Region

Bangkok

Nakhon Ratchasima

Samut Prakan

Ubon Ratchathani

Khon Kaen

Others

By Type of Laboratory in Private Hospitals

In-house Labs

Third Party Tie-Ups

Key Target Audience

Clinical Laboratory companies

Organized Clinical Laboratories

Unorganized Clinical Laboratories

Private Hospitals

Private Equity and Venture Capitalist

Industry Associations

Technology providers

Government Bodies & Regulating Authorities

Time Period Captured in the Report:

Historical Period: 2016-2021

Base Year: 2021

Forecast Period: 2022F– 2026F

Companies Covered:

Organized Labs

N Health

Pathlab

Thonburi Clinical Labs

Bangkok Medical Labs

BRIA Group

MIC Labs

Unorganized Labs

Medical Line Lab

Innotech Laboratories

Service Co., Ltd.Innolab

Prolab 

Pattaya Clinic Laboratory

CCS Medical laboratory

Excellent Pathological

Lab Company Limited

DNA Testing Laboratory Co.,Ltd.

Pathology Diagnostic Center

Ubon Pathology

Rachvipa MRI Company Limited

hi-tech lab

Bangkok Pathology-Lab

Inter-Lab Pathology and Research Center

Key Topics Covered in the Report

Thailand Clinical Laboratory Market Overview

Thailand Healthcare Overview

Ecosystem of Thailand Clinical Laboratory Market

Thailand Clinical Laboratory Market Segmentation

Industry Analysis of Thailand Clinical Laboratory Market

Value Chain of Clinical Laboratory Market in Thailand

Key Growth Drivers in Thailand Clinical Laboratory Market

End User Analysis of Thailand Clinical Laboratory Market

Key Challenges of Thailand Clinical Laboratory Market

SWOT Analysis of Thailand Clinical Laboratory Industry

Future Outlook of Thailand Clinical Laboratory Industry

Trends and Development of Thailand Clinical Lab Market

COVID-19 Impact on Clinical Laboratory Market in Thailand

For more information on the research report, refer to below link:

Thailand Clinical Laboratory Market Outlook to 2026F

Related Reports

Philippines Clinical Laboratory Market Outlook to 2027F

Indonesia Clinical Laboratory Market Outlook to 2026F (Second Edition)

Vietnam Clinical Laboratory Market Outlook to 2022 

[testing-services]

Why Apparel Testing Labs are Essential for Export-Ready Clothing

In today's globalized market, the apparel industry is more competitive than ever. With an increasing number of companies looking to expand their reach beyond local markets, exporting clothing has become a lucrative opportunity for growth. However, exporting apparel comes with its own set of challenges, particularly when it comes to compliance with international standards and ensuring that products meet safety and quality regulations.

One of the most critical steps in preparing apparel for export is ensuring it meets the standards set by the destination country. This is where apparel testing lab come into play. These specialized labs perform a variety of tests on clothing to ensure it meets the necessary regulatory requirements and industry standards for safety, quality, and performance. For apparel companies looking to expand their business internationally, partnering with an accredited apparel testing lab is essential for making products export-ready.

In this blog, we will explore why apparel testing labs are crucial for ensuring the quality, safety, and compliance of export-ready clothing and how they can benefit your business.

1. Ensuring Compliance with International Standards

One of the most significant challenges for businesses that are exporting clothing is ensuring that their products comply with the regulations of the target market. Different countries have different safety, environmental, and performance standards for apparel. Failure to meet these standards can result in delays at customs, fines, or the rejection of goods, which can be detrimental to your brand’s reputation.

Apparel testing labs play a crucial role in verifying that your clothing meets the specific requirements of the target market. For instance, countries like the United States, the European Union, and Japan have stringent regulations when it comes to the chemical content, safety, and durability of clothing. Common standards include:

REACH (Registration, Evaluation, Authorization, and Restriction of Chemicals) in the European Union

CPSIA (Consumer Product Safety Improvement Act) in the United States

ASTM (American Society for Testing and Materials) standards for safety, flammability, and durability

Testing in accredited apparel testing labs ensures that your clothing adheres to these regulations, reducing the risk of delays or fines at customs and improving your chances of successful entry into foreign markets.

2. Chemical Safety and Eco-Friendliness

One of the primary concerns when exporting clothing is the safety of chemicals used in the production process. Many countries have strict regulations regarding harmful chemicals in apparel, such as azo dyes, formaldehyde, and phthalates, all of which can have harmful effects on consumers’ health and the environment. This is particularly important for children’s clothing, which is subject to even stricter regulations due to the sensitivity of young skin.

Accredited apparel testing labs perform a range of chemical safety tests to detect harmful substances in fabrics and finished garments. Tests for:

Azo dyes: Which can release carcinogenic amines when washed.

Formaldehyde: Which is commonly used in fabric finishing but can cause allergic reactions and skin irritation.

Phthalates: Used as plasticizers but can disrupt the endocrine system.

Moreover, eco-friendly certifications like OEKO-TEX® Standard 100 and Global Organic Textile Standard (GOTS) are becoming more popular. These certifications not only show compliance with regulations but also demonstrate your commitment to sustainability. Apparel testing labs help your company meet these eco-friendly standards, making your products more appealing to environmentally conscious consumers.

3. Performance Testing for Durability and Functionality

For export-ready apparel, durability is an essential factor that cannot be overlooked. Different markets may have varying expectations for how clothing should perform under specific conditions, such as exposure to UV rays, moisture, or frequent washing. To ensure your clothing performs well throughout its lifespan, apparel testing labs conduct a variety of tests on materials and finished garments, including:

Tensile strength tests: To measure fabric resistance to stretching and tearing.

Abrasion resistance tests: To ensure that garments will hold up against regular wear and tear.

Shrinkage tests: To determine how much the clothing will shrink after washing, an essential consideration for both manufacturers and consumers.

Colorfastness tests: To check how well the colors hold up under washing, sunlight, and other environmental factors.

By working with apparel testing labs, you can ensure that your products meet the performance expectations of the target market, reducing the likelihood of returns and improving customer satisfaction.

4. Flammability Testing for Safety Compliance

Flammability is another critical safety concern, particularly for children’s apparel, sleepwear, and home textiles. Several countries have stringent flammability regulations to ensure that clothing does not pose a fire hazard. For instance, the CPSIA in the U.S. mandates specific flammability standards for children’s clothing, while the BS EN 14878 standard is used in the EU for sleepwear.

Apparel testing labs specialize in flammability testing to ensure that clothing complies with these safety regulations. Testing typically includes:

Fabric burn rate tests: To measure how quickly the fabric ignites and burns.

Sleepwear flammability tests: To ensure that children’s clothing, especially pajamas, meets the required standards for flame resistance.

Flammability testing in accredited labs helps prevent costly recalls, potential lawsuits, and, most importantly, protects consumers by ensuring that their clothes are safe to wear.

5. Building Consumer Trust with Certification

In today’s market, consumers are increasingly concerned about the safety, quality, and environmental impact of the products they buy. By ensuring that your clothing passes the rigorous tests set by apparel testing labs, you can boost consumer trust in your brand. Certifications from reputable testing organizations like OEKO-TEX® or GOTS not only provide proof of quality but also signal to consumers that your products have been carefully tested for safety and sustainability.

These certifications act as a valuable marketing tool, helping your brand stand out in the competitive global market. Consumers are more likely to trust products that come with certified guarantees, leading to increased sales and customer loyalty.

6. Cost Savings and Risk Reduction

Although working with an apparel testing lab incurs costs, the long-term benefits often outweigh the initial investment. Apparel testing ensures that your products comply with international regulations, reducing the risk of customs delays, fines, or rejected shipments. Additionally, testing helps prevent costly product recalls, which can damage your brand’s reputation and lead to significant financial losses.

Testing your apparel before export also reduces the risk of producing faulty products. By identifying potential issues early on in the production process, you can make necessary adjustments to avoid defects and ensure that the final product meets customer expectations. This proactive approach to quality control can save money on returns and customer complaints.

7. Streamlined Export Process

When it comes to exporting apparel, time is of the essence. The faster your products are ready for market, the quicker you can realize revenue from your international customers. Apparel testing labs streamline the testing and certification process, providing fast turnaround times and ensuring that you meet the deadlines for export.

Accredited labs understand the specific requirements for different markets and can guide you through the testing process, ensuring that your products are export-ready without unnecessary delays. Their expertise ensures that you avoid costly mistakes, such as missing deadlines or failing to meet regulatory requirements.

Conclusion

In the highly competitive global apparel market, ensuring that your products are export-ready is essential for success. Apparel testing labs play a critical role in helping brands meet the safety, quality, and regulatory standards required for international markets. By partnering with an accredited lab, you can ensure that your clothing meets the necessary compliance standards, performs well in various conditions, and is safe for consumers. Furthermore, working with testing labs helps you build consumer trust, reduce risks, and streamline the export process.

Whether you're expanding your business into new markets or striving to maintain your competitive edge, apparel testing labs provide the expertise and support necessary for success. With the right testing partner, your products can be certified, compliant, and ready for global distribution.

[onenettvchannel]

CONSUMER HEALTH NEWS: 'BAN Toxics' launches Holiday Ber-months Campaign against Hazardous Toys for the Filipino shopping consumers

MANDALUYONG, MANILA -- Calenderic 'Ber' months are now approaching, particularly with the annual and upcoming yuletide season, the environmental non-government organization 'BAN Toxics' has just initiated an important awareness campaign in the 1st week of September this year in 2024, to protect Filipino children from the hazards of toxic toys. As the year-end holiday seasons are usually associated with gift-giving, the organization released an educational infographic titled "Mag-Ingat sa mga Laruang Toxic! (Beware of Toxic Toys!)" teaching all of its consumers to watch out for toxic chemicals that may be hiding in toys, especially those sold at neighborhood markets and cheap bargain shops.

(ART PHOTO COURTESY: BAN Toxics via PR / A female kid sat toxic toy to be disguised as a playable friend)

The infographic, as presented digitally and in traditional pamphlet-like papers, shows that there is a wide variety of toxic chemicals, including Lead, Phthalates, Cadmium, Bisphenol A (BPA), Chromium, Formaldehyde, Bromine, Chlorinated Paraffins, Mercury and Arsenic. Many of these chemical additives might be used in the manufacturing processes from factories, and could create very serious health risks for our children.

Mr. Thony Dizon, who is a campaign and advocacy officer of 'BAN Toxics', many of those toys lacked proper labeling and safety information, meaning they may not have been tested correctly, or complied with health and safety regulations. All toys sold in the Philippines were supposed to be affixed with safety labeling under the Republic Act #10620, also called the "Toy and Gaming Safety Act of 2013", but many products still manage to slip through.

The toxic nature of such chemicals exposes humans to alarming health implications, as exposures may cause a variety of diseases that may include endocrine disruption, carcinogenicity and neurotoxicity; several of which, may persist throughout childhood and even thereafter in our adulthood life.

Dizon urges lawmakers in the nationals, to prioritize the legislation of the "Safe and Non-Hazardous Children's Products Law", a newly-proposed measure which provides for tighter regulation of the importation, manufacture, distribution, and sale of toys and other children's products containing hazardous chemicals. This forthcoming legislative drive is relevant to ensure safeguards for the kids against substances that could jeopardize their health and well-being.

In addition to the infographic, BAN Toxics plans to distribute thru partner schools and communities through their Toxic and Waste-Free Schools Program (TFSP), which potentially later expanded here in the Visayas and Mindanao regions, including Dumaguete City, Bacolod City, Negros Occidental and Negros Oriental. This is to ensure that there is always an assurance of the safest and cleanest environment in schools, including these examples of 'West City Elementary School' and 'Magsaysay Memorial Elementary School', while also educating children on the risks and giving them a head start on making legitimate and responsible choices about the toys they play with.

The Food and Drug Administration (FDA) in the Philippines plays a very crucial role in this regard through periodic issuance of advisories on the proper use of toys, including those with mandatory labeling. It has taken charge in conducting research and testing of available toys and childcare articles in the market and is presently drafting an administrative order containing product standards on chemicals to be at par with international guidelines. Meanwhile, the Department of Trade and Industry (DTI) has established the Philippine National Safety Standard (PNSS) for toys, in response to the International Organization for Standardization (ISO).

'BAN Toxics' is committed to continuous market monitoring and testing of toys, and more activities are planned for the coming months to keep the public informed of any new findings. As the 'Ber' months are just around the corner, it is now high-time for consumers to be more vigilant and informed about the toys they are going to buy, whether in-store or online.

Today, and for the future, the unveiling of "Mag-Ingat sa mga Laruang Toxic!" continually reminds us that even in seemingly innocent gifts, the worm of hazard may be concealing itself. Through awareness and a call for better regulations, 'BAN Toxics' hopes to protect the health of Filipino children and ensure that the joy of giving is not transposed into an act at the expense of their safety. Even when Santa Claus should check first, without secretly adding toxics in toys.

ART PHOTO COURTESY: BAN Toxics via PR BACKGROUND PROVIDED BY: Tegna

-- OneNETnews Online Publication Team

[industryforecastnews]

Aquatic Ecotoxicological Studies Market To Reach USD 750.9 Million By 2030

Aquatic Ecotoxicological Studies Market Growth & Trends

The global aquatic ecotoxicological studies market size is expected to reach USD 750.9 million by 2030 and grow at a CAGR of 7.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is driven by growing environmental awareness, the potential risk of toxic substances on aquatic organisms, and the increasing need for ecotoxicological studies to identify and assess environmental risks and ensure compliance with environmental regulations.

Furthermore, increased focus on environmental sustainability and the requirement for regulatory practices to characterize the long-term effects of toxic substances on aquatic ecosystems and pollution-related issues have fueled the market. Likewise, the studies provide crucial insights into pollutant behavior, bioaccumulation, and ecological pathways, helping to prevent environmental disasters and protect human health. Moreover, the companies are significantly focusing on developing formulations and solutions with lesser threats and adverse impacts on environmental entities. Hence, aquatic ecotoxicological studies are crucial to evaluate the safety of these newly developed formulations on aquatic life before their widespread use.

In addition, the market is significantly growing, with players offering various testing services such as acute toxicity tests, chronic toxicity tests, bioaccumulation studies, biodegradation studies, and others, propelling the market growth. In addition, the growing expansion of facilities for aquatic ecotoxicological studies in various regions across the globe is gaining momentum, driven by a growing demand for environmentally friendly and sustainable options. For instance, in October 2022, Charles River Laboratories announced the ecotoxicology expansion of its 16,000 m2 site to meet the growing demand for various time-critical testing programs. In addition, the company has completed the construction of six new ecotoxicology laboratories and has upgraded its existing facilities. At its Den Bosch site, the company will now offer expertise in ecotoxicology, toxicology, and environmental risk assessments. Additionally, new facilities will include a custom-designed fish culture system for aquatic ecotoxicology studies. Besides, in early 2023 the testing volumes performed are expected to increase when changes to endocrine disruptor testing requirements. This expansion will allow the company's clients to effectively continue their studies in accordance with regulatory changes.

Some of the key players in the market are SGS SA, Charles River Laboratories Inc., Laboratory Corporation of America Holdings, Toxi-Coop Ltd., and others. Market players are adopting key strategic initiatives to boost their market presence and expand their business. For instance, in October 2022, EcoAnalysts, Inc. announced its expansion in Florida after its acquisition of Hydrosphere Research Environmental Services, an aquatic ecotoxicity testing service provider.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/aquatic-ecotoxicological-studies-market-report

Aquatic Ecotoxicological Studies Market Report Highlights

Based on type, the acute toxicity tests segment dominated the market in 2023. The segment growth is driven by the increasing lethal concentrations of a substance in the aquatic ecosystem rising need to meet global regulations across the chemical sector before the products are marketed, including pharmaceuticals, agrochemicals, biocides, and industrial chemicals.

Based on end use, pharmaceuticals held the largest market share of 39.4% in 2023. The segment growth is driven by significant penetration of aquatic ecotoxicological studies in the pharmaceutical industry to assess the impact of pharmaceutical products and their active pharmaceutical ingredients (APIs) on aquatic organisms and ecosystems.

Furthermore, in terms of pharmaceuticals, the human medicine sub-segment held the largest market share in 2023. The segment is driven by the growing adoption of sustainable practices and the increasing need to meet environmental safety standards, contributing to its prominence in this field.

Europe dominated the aquatic ecotoxicological studies market with a share of 32.5% in 2023. The region's growing pollution in European countries has led to an increasing requirement for ecotoxicological studies to assess the toxicity of chemicals and further detect the effects in the ecosystems caused by the pollutants, contributing to market growth.

Aquatic Ecotoxicological Studies Market Segmentation

Grand View Research has segmented the global aquatic ecotoxicological studies market based on type, end-use, and region:

Aquatic Ecotoxicological Studies Type Outlook (Revenue, USD Million, 2018 - 2030)

Acute Toxicity Tests

Chronic Toxicity Tests

Bioaccumulation Studies

Biodegradation Studies

Others

Aquatic Ecotoxicological Studies End-use Outlook (Revenue, USD Million, 2018 - 2030)

Pharmaceuticals

Human Medicine

Veterinary Medicine

Biocides

Agrochemicals

Chemicals and Petrochemicals

Others

Aquatic Ecotoxicological Studies Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

U.S.

Canada

Mexico

Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

Netherlands

Switzerland

Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

Latin America

Brazil

Argentina

Middle East and Africa (MEA)

South Africa

Saudi Arabia

UAE

Kuwait

List of Key Players in the Aquatic Ecotoxicological Studies Market

Charles River Laboratories, Inc.

SGS SA

Laboratory Corporation of America Holdings

Smithers

Aragen Life Sciences Pvt. Ltd.

Fera Science Limited

Noack Laboratorien GmbH

Eurofins Agroscience Services Group

ibacon GmbH

BRF (Bioscience Research Foundation)

Toxi-Coop Ltd.

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/aquatic-ecotoxicological-studies-market-report

[de-temple]

Essential Oils – Digging Deeper Lavender Oil - Center for Research on Ingredient Safety

"Are lavender essential oils safe?

Some research suggested that lavender oil could have estrogenic effects, meaning they could disrupt the endocrine system and cause adverse health effects, especially in young male children (1,2). Without scientific consensus, researchers continue to conduct new projects on lavender use to see what, if any adverse endocrine disruptions occur (1,2,3).

 

Edible lavender, commonly known as culinary lavender, used in teas, for baking, and more is typically a different species of lavender plant grown specifically for human consumption and is usually sold as dried flowers. Food-grade lavender oils and extracts differ from lavender essential oils designed for fragrances. It’s important to always check the label to ensure you’re using the correct product. The FDA classifies consumable lavender products as GRAS ingredients.

 

The ingredients in essential oils and products designed for topical use or through scent are not grown, tested, or intended for human consumption.

 

If you’re allergic lavender, you should avoid products and foods that contain lavender."

https://www.canr.msu.edu/news/essential-oils-digging-deeper-lavender-oil#:~:text=Are%20lavender%20essential,that%20contain%20lavender.

[marketsndata]

Global Semen Analysis Market Size, Share, Growth and Forecast 2031

Global semen analysis market is projected to witness a CAGR of 5.05% during the forecast period 2024-2031, growing from USD 1,552.23 million in 2023 to USD 2,302.11 million in 2031. The global semen analysis market is expected to keep growing at a robust pace during the forecast period owing to rising awareness about reproductive health, growing cases of infertility, lifestyle habits, and heavy emphasis on diagnosis and treatment of infertility cases from the user end.

Semen analysis, or sperm count analysis, evaluates sperm health by measuring sperm count, motility, and morphology. Products and services in this market include laboratory testing, at-home sperm count kits, and fertility consultations, all aimed at diagnosing male infertility and guiding treatment options. Over the last decade, society has witnessed a huge change in lifestyle and food habits that severely impacted overall human health, including fertility. These changes, coupled with growing awareness about reproductive health, advancements in diagnostics, growing preference for male health, and innovative product launches and services, further enhance the semen analysis market growth. Product launch and market expansion further fuel the market growth; for instance, DYNEVAL LTD. launched its portable semen analyzer, Dynescan, in Bolivia in April 2024, following a successful visit during the DBT Agri-Tech Trade Mission. The partnership with Union Agronegocios SRL aims to enhance the quality assurance of semen during transport and storage. The analyzer features a new fertility marker, SML (Sustained Motility Lifetime), which could improve conception rates by up to 8%.

Growing Cases of Male Infertility Boosts Market Growth

The growing prevalence of male infertility is a significant driving force for the growth of the semen analysis market. Factors such as unhealthy lifestyles, environmental pollutants, and rising stress levels contribute to declining sperm quality globally. Apart from these, exposure to endocrine disruptors and pollutants like pesticides, heavy metals, and industrial chemicals have been linked to reduced fertility. As more couples face challenges with conception, the demand for comprehensive fertility assessments, including semen analysis, continues to rise. The increasing incidents of male infertility are becoming not only a pressing issue but also a growth stimulus in the semen analysis market. Awareness and technological innovation boost demand for accurate yet accessible semen testing. These trends form a dynamic climate both for healthcare providers and manufacturers as they open the scope for innovative investment in the realm of reproductive health. For instance, according to the Human Reproduction Programme (HRP) annual report published in April 2023, globally, 1 in 6 people are estimated to be affected by infertility. In another study published in the “Human Reproduction Update” journal, the global sperm counts fell on average by 1.2% per year between 1973 to 2018, from 104 to 49 million/ml, and year 2000 afterward, this rate of decline accelerated to more than 2.6% per year.

Rising Awareness About Fertility Testing Drives Market Growth

Growing awareness about fertility testing is an essential driving force for the semen analysis market. Societal attitudes regarding the need for greater openness over reproductive health issues are helping raise people’s awareness about male fertility playing an important part in general couple infertility, accounting for a significant share of the global prevalence of infertility. Advocacy groups and healthcare organizations are now conducting public awareness campaigns on male infertility to educate people about testing sperm count. Public awareness campaigns, demystifying the whole process and encouraging men to seek tests increase the demand for semen analysis services. Therefore, the semen analysis market growth is primarily dependent upon increasing awareness of fertility testing. Public awareness and education, technical innovations in technology, the changes brought about in lifestyles, access to improved healthcare facilities, and even the comfort of online purchase options inspire men to address their reproductive concerns actively. Along with the continued removal of the social stigma related to such topics and through enhanced awareness, semen analysis services will grow enormously during the next couple of years.

For instance, every year, the last week of April is celebrated as National Infertility Awareness Week to spread awareness about infertility and its management options. Several organizations, like the American Society for Reproductive Medicine and the National Infertility Association, run various campaigns to spread awareness about the same.

Dominance of Fertility Centers Segment in Market

Fertility centers specialize in a broad spectrum of reproductive health services. They are important to the couple suffering from infertility. A proper evaluation, such as a sperm function test, is essential for developing individualized treatment plans. The ability to take a holistic approach from the first testing process to the possible treatments of in-vitro fertilization positions and fertility centers forms an integral part of the sperm analysis market. Having had a significant market share, increased awareness of male infertility, the rapid advancement of modern technology in diagnostic practices, and extensive services within a fertility center cement these leaders within the market on sperm analysis. Because trends may always take an evolving path forward, then fertility centers stand tall and firm in this future trend on addressing the concerns associated with male infertility using appropriate approaches through sperm analysis and related interventions.

In July 2024, Legacy, a leading digital fertility clinic for men, introduced an upgraded at-home sperm testing and freezing kit. This new version features a patented conical collection cup for accurate volume reporting, enhanced insulation for temperature control, and a tamper-proof padlock seal. Designed based on client feedback, the kit aims to improve user experience and security. Legacy continues to prioritize accessibility in fertility preservation, reflecting its commitment to customer service and innovation in male reproductive health.

North America Dominates the Semen Analysis Market

North America is anticipated to be the dominant region in the semen analysis market. This leadership is driven by advanced healthcare infrastructure, high adoption of innovative technologies, and increased awareness of male reproductive health issues. The region benefits from robust research and development activities, leading to the introduction of cutting-edge sperm testing products. Additionally, supportive government policies and favorable reimbursement frameworks boost market growth. The rising prevalence of male infertility and the demand for assisted reproductive technologies further solidifies North America’s position as a leader in this sector. Additionally, authorities in the region also contribute to the market expansion through their efforts; for instance, the American Urological Association (AUA), in collaboration with the American Society for Reproductive Medicine (ASRM), has released the 2024 amendment to its Male Infertility Guideline. This updated guideline offers a comprehensive approach to evaluating and managing male infertility, emphasizing thorough patient history, physical exams, and necessary diagnostic testing. Key updates include recommendations on azoospermia evaluation, karyotype testing, imaging modalities, and the use of testicular sperm in non-azoospermic patients. Additionally, it revises WHO reference ranges for semen characteristics and introduces a new table defining common semen analysis terms, aiming to improve male reproductive health and overall well-being.

Download Free Sample Report

Future Market Scenario (2024-2031F)

Futuristic advancements in the analysis of sperm, in particular, reform much of the market with the integration of AI and advanced imaging technology. Traditional semen analysis, being manual, allows considerable subjectivity and a plethora of human errors wherein such variability goes into determining results. The alternative given to this is that AI-driven semen analysis gives a structured approach that is devoid of as much human intervention, lending towards a standardized measure for assessing parameters of semen related to sperm count, motility, and even morphology. AI technologies rapidly process images through advanced algorithms such that thousands of sperm images are analyzed with unprecedented precision. Automating these results reduces turn-around times and creates laboratory workflow streams for fast, efficient sperm analysis. Another aspect of AI is predicting the male potential for fertility, taking information from multiple points, whether in medical history or personal life, thereby allowing individually targeted treatment. The advent of automated systems, including computer-aided sperm analysis (CASA), will further support these developments. These systems can provide reliable diagnostics that improve clinical decision-making. The promise of improved male reproductive health outcomes and access to fertility assessments through the continued evolution of these technologies will further transform the landscape of fertility evaluation and treatment.

Report Scope

“Semen Analysis Market Assessment, Opportunities and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global semen analysis market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Click here for full report- https://www.marketsandata.com/industry-reports/semen-analysis-market

Latest reports-

Contact

Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: info@marketsandata.com Website: https://www.marketsandata.com

[trendingreportz]

Cancer Testing Screening Market - Forecast(2024 - 2030)

Cancer Testing Screening Market Overview

Cancer Testing Screening Market size is projected to reach $220.66 billion by 2027 and is expected to grow at a CAGR of 6.4% during the forecast period 2022-2027. Cancer Testing and Screening are vital procedures for aid in the early detection of cancer before symptoms occur. It lowers the risk of malignant cells growing abnormally and lowers the person's mortality rates. Each type of cancer has a screening test that can help spot cancer early on. There is increasing adoption of cancer screening tests, particularly in countries with the highest cancer rates. The improved research and development activities coupled with the increasing public awareness of cancer diseases are all predicted to create a new window of opportunities in the global cancer Testing screening market. However, COVID-19 has restrained the market growth. The lack of adequate supplies needs for more service providers added to the crises, thereby restraining the market growth.

Cancer Testing Screening Market Report Coverage

The report: “Cancer Testing Screening Market Forecast (2022-2027)”, by Industry ARC, covers an in-depth analysis of the following segments of the Cancer Testing Screening Market.

By Type: Diagnostics, Screening. By Cancer Type: Respiratory System Cancer, Leukemia, Myeloma and Lymphoma, Skin Cancer, Abdominal/Digestive System Cancer, Genital Cancer, Oral Cancer, Urinary System Cancer, Endocrine System Cancer, Breast Cancer, Others. By Technique: Imaging, Biopsy, Genomic and Molecular Tests (Next Generation Sequencing, RT-PCR, Microarrays, Biomarker Testing, Others. By Product Type: Molecular Diagnostics, Companion Diagnostics. By Stage: Terminal, Stage 0-4, Prognosis, Other Staging System. By Gender: Male, Female. By Geography: Americas (U.S, Canada, Brazil, Rest of Americas), Europe (U.K, Germany, France, Italy, Spain and Rest of Europe), Asia-Pacific (China, Japan, India, and South Korea), and Rest of the World (Middle East, Africa).

Request Sample

Key Takeaways

Geographically, The Americas Cancer Testing Screening market accounted for the highest revenue share in 2021, followed by Europe. This is owing to the steady rise of Lung and Prostate Cancer cases in both regions which are being driven by the adoption of unhealthy lifestyles such as excessive alcohol consumption and smoking.

The increasing number of cancer cases around the world is unfortunate. However, it is beneficial to the cancer screening industry. The industry is also being propelled forward by Increased research and development (R&D) to develop effective cancer treatments and early detection. Innovative technologies including positron emission mammography, spectroscopy-enhanced colonoscopy, and hyperpolarization MRI, among others, are improving screening efficiency.

Cancer Testing Screening Market Detailed Analysis on the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Cancer Testing Screening Market report.

Cancer Testing Screening Market Segment Analysis – By Cancer Type

The Cancer Testing Screening Market based on Cancer Type can be segmented into Respiratory System Cancer, Leukemia, Myeloma, and Lymphoma, Skin Cancer, Abdominal/Digestive System Cancer, Genital Cancer, Oral Cancer, Urinary System Cancer, Endocrine System Cancer, Breast Cancer, and Others. Abdominal/Digestive system cancer had the largest share in the cancer testing screening market in 2021 and is expected to grow at a CAGR of 5.9% owing to the rise in consumption of processed food and alcohol. Additionally, the increase in the global geriatric population has generated demand for imaging devices for early detection and treatment of Abdominal cancer, thereby driving the segment. According to the Organization of the United Nations, the proportion of people aged 65 and up in the global population climbed from 6% in 1990 to 9% in 2019. By 2050, that percentage is expected to climb to 16%, implying that one in every six individuals on the planet is predicted to be 65 or older.

Inquiry Before Buying

Cancer Testing Screening Market Segment Analysis – By Technique

The Cancer Testing Screening Market based on the Technique can be segmented into Imaging, Biopsy, Genomic and Molecular Tests (Next Generation Sequencing, RT-PCR, Microarrays, Biomarker Testing, and Others. Biopsy technique dominated the Cancer testing screening Market in 2021 and is expected to grow at a CAGR of 6.2%. This is owing to its high accuracy during Cancer Diagnosis. Other Diagnostic advances, such as imaging techniques, have increased demand for cancer testing and screening. Imaging has become an important aspect of cancer detection and diagnosis, with recent advancements in tumor imaging technologies improving the diagnosis of five common cancers, including breast, lung, prostate, and colorectal cancers.

Cancer Testing Screening Market Segment Analysis – By Geography

The Cancer Testing Screening Market based on Geography can be segmented into Americas, Europe, Asia-Pacific, and the Rest of the World. Americas region dominated the cancer screening/testing market in 2021 with a market share of 41% and is growing at a CAGR of 4.5% during the forecast period 2022-2027. This is owing to the high rate of new cancer cases each year along with increased awareness amongst the masses.

 However, Asia Pacific is set to be the fastest-growing segment with a CAGR of 11% during the forecast period 2022-2027. This is owing to the growing rate of endocrine, abdominal, leukemia, myeloma, and lymphoma cancers in the Asia Pacific region. 

Schedule a Call

Cancer Testing Screening Market Drivers

Growing Number Of Cancer Screening Awareness Campaigns To Raise Awareness About The Importance Of Early Detection Of Breast Cancer Is To Drive Market Growth

Several governmental and commercial groups are launching various campaigns to raise awareness about the importance of early detection of breast cancer, the second most frequent cancer among women in the United States. Breast Cancer Diagnostics Market Growth Depends on Cancer Awareness Campaigns. Nations around the globe have initiated various Cancer Screening Awareness Campaigns to encourage young people to make these life-saving behaviors part of their daily routine. For example, Breast cancer campaigns, Cervical cancer awareness campaigns, Protect Your Skin campaigns, Ovarian cancer awareness campaigns and Colorectal cancer awareness campaigns are among the few impacting the growth of the cancer screening and diagnostics market. For instance, the 'Be Clear on Cancer campaign has substantially increased the number of referrals under the 2WW rule. This has increased demands on both resources (59% more tests) and finance. Cost per cancer detected rose by 27% with no increase in funding to support the increased activity.

Technological Advancements And Automation In Cancer Testing And Screening Is To Fuel Service Demand

Cancer testing has become more accurate and user-friendly as a result of technological developments and automation, which has aided industry growth. Novel screening technologies have largely been adopted owing to their ability to increase tumor detection rates. Additionally, the cancer testing & screening market is likely to be driven by the approval of novel biomarkers and increased R&D spending. The key players in the market are increasingly investing in AI-based imaging biomarkers. For instance, Brainomix has invested $21.2 million for the development of an AI platform that automates validated imaging biomarkers to improve both diagnosis and treatment decisions to build on the proven success of the company's tech platform in stroke and enable value-generating pharmaceutical partnerships. Proteomics and genomics are two OMICS technologies that will propel the cancer testing & screening industry forward.

Cancer Testing Screening Market Challenges

High Cost Of Cancer Diagnosis And Increased Financial Burden To Hamper The Market Growth

Cancer has a significant financial impact on patients and their families. Today, the estimated 16.1 million cancer patients face annual out-of-pocket medical expenses that are 61% higher than those who do not have cancer. Cancer patients had higher out-of-pocket costs than non-cancer patients, with high-deductible health plans having the greatest out-of-pocket costs. According to a report by the National Coalition of Cancer Survivorship 47% of cancer patients reported financial burden in cancer care.

Buy Now

Cancer Testing Screening Industry Outlook

Product Launch, Collaboration, and Acquisitions key strategies adopted by players in the Cancer Testing Screening Market. In 2020, the Cancer Testing Screening Market share is consolidated by the top ten players present in the market. In the Cancer Testing Screening Market, the top 10 companies are-

DiaSorin S.p.A

Immunodiagnostic Systems Holdings Ltd

Epigenomics AG

Quest Diagnostics Inc.

F. Hoffmann-La Roche Ltd

VolitionRX Limited

Abbott Laboratories

QIAGEN GmbH

Siemens Healthineers AG

Becton, Dickinson, and Company

Recent Developments

In January 2022, Siemens Healthineers, through its subsidiary Varian entered into a ten-year strategic partnership with Oulu University Hospital in Finland, to build a comprehensive digital, diagnostic and therapeutic ecosystem that addresses the entire cancer treatment pathway. Siemens will supply a technology and services package to Oulu University Hospital that includes cancer imaging and radiation therapy equipment, software solutions for enhanced workflow and decision support, and related support services.

In February 2022, Becton, Dickinson, and Company acquired Cytognos, a company specializing in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection, and immune monitoring research for blood diseases. The acquisition enables BD to enhance chronic illness management by increasing its offering of blood cancer diagnostics, immunological assessment tests, and informatics.

In October 2021, Roche entered into a collaboration with PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology. Under the agreement, the companies are to jointly develop an embedded image analysis workflow for pathologists, which can benefit cancer patients through more precise diagnosis. 

[mitalipingale]

The Endocrine Peptides Test Market in 2023 is US$ 8.24 billion, and is expected to reach US$ 15.51 billion by 2031 at a CAGR of 8.22%.

[peptide-ltd]

CagriSema, Cagrilintide&Semaglutide, new peptide in Phcoker 2024!

Novo Nordisk “Cagrilintide/semaglutide” Research

Cagrilintide and Semaglutide overview

Cagrilintide: As a non-selective agonist for both amylin receptor (AMYR) and alcitonin G protein-coupled receptor (CTR), it confidently reduces food intake, resulting in significant weight loss. Cagrilintide peptide is an exciting amylin analog that has shown strong potential in the study of obesity. Cagrilintide is currently being tested alone and in combination with Semaglutide for the treatment of obesity and type 2 diabetes.

Semaglutide: Semaglutide is an amazing peptide belonging to the class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs)! This medication is truly a game-changer! It expertly mimics the GLP-1 hormone, significantly increases insulin release, effectively lowers glucagon release, expertly delays gastric emptying, and greatly reduces appetite.

Cagrilintide/semaglutide: A fixed dose combination of Cagrilintide and Semaglutide is under development for the treatment of type 2 diabetes, obesity and metabolic dysfunction-associated steatohepatitis (MASH). It administered through subcutaneous route. Cagrilintide is a long-acting amylin analogue which acts by targeting calcitonin receptor, receptor activity modifying proteins 1, 2, 3 (RAMP 1-3) and semaglutide acts by targeting glucagon like peptide 1 receptor (GLP1R).

Novo Nordisk overview

Novo Nordisk, a subsidiary of Novo Holdings AS, is a healthcare company focused on discovering, developing, and manufacturing innovative biological medicines. It focuses on advancing drugs for the treatment of diabetes and other serious chronic conditions, including hemophilia, human growth hormone (HGH) disorders, rare blood and rare endocrine diseases, and obesity.

Cagrilintide/semaglutide Researches

【REDEFINE 2】A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

Brief Summary: This study will look at how well the new medicine CagriSema helps people living with excess body weight and type 2 diabetes losing weight. Participants will either get CagriSema or a dummy medicine. Which treatment they get is decided by chance. It will last for about 1.5 years. Women cannot take part if pregnant, breast-feeding or planning to get pregnant during the study period.

Official Title: Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity and Type 2 Diabetes

【REDEFINE 3】A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

Brief Summary: This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular disease. Participants will either get CagriSema or a dummy medicine (also called “placebo”) which has no effect on the body. Which treatment participants will get will be decided by chance. Participant’s chance of getting CagriSema or placebo is the same. Participants will inject the study medicine once a week. The study medicine will be injected briefly with a thin needle, typically in the stomach, thighs or upper arms. The study will last for up to 4.5 years.

Official Title: The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease

The review of CagriSema’s researches provides a comprehensive understanding of its background, effects, and development direction. CagriSema powder is an emerging weight-loss peptide in the market, and only a few manufacturers have mastered its production technology. For research purposes, we recommend purchasing from Phcoker, which offers GMP pharmaceutical-grade quality to meet your needs and provide reliable answers to your questions.

What Is CagriSema Peptide? Is it Cagrilintide?

CagriSema peptide, the combination of Cagrilintide and Semaglutide, indeed presents a promising approach in the treatment of both obesity and type 2 diabetes. The synergy between these two medications seems to offer greater therapeutic benefits than either drug alone, as evidenced by the preliminary trial results showing significant weight loss and improved glycemic control.

Individuals seeking weight management often opt for Semaglutide due to its efficacy, and the potential of CagriSema to deliver even more powerful results is understandably appealing. The Phase II trial results, demonstrating a substantial average weight loss of -15.6% after 32 weeks, reinforce the potential of CagriSema as a formidable option in weight management.

The upcoming head-to-head trial comparing CagriSema to Tirzepatide will provide crucial insights into their comparative efficacy and safety profiles, aiding clinicians in making informed treatment decisions for their patients. The continued advancement of CagriSema into Phase III trials underscores its potential to address the complex challenges posed by type 2 diabetes and obesity.

Overall, CagriSema represents an exciting development in the field of metabolic disorders, offering hope for improved outcomes and better quality of life for individuals struggling with these conditions.

CagriSema Ttherapy

The progression of Cagrilintide and Semaglutide combination therapy (CagriSema) into Phase III for type 2 diabetes represents a significant milestone in its clinical development. With Novo Nordisk spearheading this effort, the focus is on evaluating its efficacy and safety in a larger population of patients.

The Phase III stage is pivotal, as it provides further insights into the drug’s effectiveness, potential side effects, and overall risk-benefit profile. The fact that it has advanced to this stage indicates promising results from earlier phases and underscores the interest in its therapeutic potential.

GlobalData’s benchmark of a 52% phase transition success rate (PTSR) for Phase III drugs in type 2 diabetes highlights the challenges associated with advancing treatments in this field. However, it’s important to note that each drug and clinical trial is unique, and success rates can vary based on various factors such as the mechanism of action, study design, patient population, and safety profile.

As CagriSema progresses through Phase III trials, its performance will be closely monitored, with the ultimate goal of demonstrating its efficacy and safety to regulators and healthcare providers. If it meets the desired endpoints and safety criteria, it could potentially advance to pre-registration, bringing us closer to offering a new treatment option for individuals living with type 2 diabetes.

What Benefits Can You Get From CagriSema?

CagriSema holds promise as a comprehensive treatment option for individuals with type 2 diabetes and obesity, offering a combination of glycemic control, weight loss, appetite regulation, and potential cardiovascular benefits.

CagriSema for Managing Type 2 Diabetes

CagriSema, a combination of Cagrilintide and Semaglutide, is a promising treatment for type 2 diabetes. The individual efficacy of Cagrilintide and Semaglutide in improving glycemic control and aiding weight loss makes the combination therapy an intriguing prospect for managing type 2 diabetes.

Ongoing clinical trials, including Phase II and Phase III studies, are evaluating the safety and efficacy of CagriSema specifically in patients with type 2 diabetes. Early results from these trials confidently indicate that CagriSema can provide greater benefits for weight loss and glycemic control compared to either medication alone.

The diplomatic dual mechanism of action, which combines the effects of a GLP-1 agonist (Semaglutide) with a dual amylin and calcitonin receptor agonist (Cagrilintide), may lead to synergistic effects, resulting in improved outcomes for patients with type 2 diabetes.

As more research is conducted and additional data becomes available, clinicians will gain a better understanding of the potential role of CagriSema in managing type 2 diabetes. If proven to be both effective and safe, CagriSema could be a valuable addition to the current treatments available for this complex metabolic disorder.

Cagrisema for Weight Loss

CagriSema peptide is a highly promising treatment for weight loss, particularly in individuals with obesity or overweight conditions. The two components of CagriSema, Cagrilintide and Semaglutide, work through different mechanisms of action to effectively reduce body weight.

Cagrilintide, a dual amylin and calcitonin receptor agonist, regulates appetite and food intake by acting on the central nervous system. Semaglutide, a GLP-1 receptor agonist, reduces food consumption and induces satiety, leading to decreased calorie intake. It mimics the action of the natural hormone GLP-1, which is released in response to food intake and promotes feelings of fullness, thereby reducing appetite and calorie consumption. This medication has been shown to be effective in clinical trials and is a promising option for those looking to manage their weight.

CagriSema powder is a highly effective weight loss treatment that combines Cagrilintide and Semaglutide. The results of early clinical trials and research have been very promising, with participants experiencing significant reductions in body weight when treated with CagriSema.

By combining two medications with complementary mechanisms of action, it offers a promising approach to weight loss. CagriSema in Phcoker has the potential to be a novel and valuable treatment option for managing obesity and overweight conditions. As more data become available and research progresses, CagriSema is likely to become an increasingly important tool in the fight against obesity.

Cagrisema for Cancer Treatment

Cagrisema (omacetaxine mepesuccinate) is a prescription medication used to treat chronic myeloid leukemia (CML). It is a type of chemotherapy drug that works by targeting certain proteins on the cancer cells, which helps to stop the growth of the cancer cells. Cagrisema is typically administered as an injection under the skin and must be taken daily for up to 18 months.

It is important to note that while CagriSema is still undergoing clinical development, it has shown promising results in weight management. However, further research is needed to fully understand its efficacy, safety, and long-term effects. As with any medication, it may not be suitable for everyone and should be used under the guidance of a healthcare professional. Phcoker is a trustworthy peptide supplier, with sales staff providing online guidance and providing the best quotations and logistics.

[testing-services]

How Cosmetic Testing Labs Protect Consumers by Testing for Harmful Ingredients and Contaminants

The beauty and personal care industry is a multi-billion dollar market, offering a wide range of products designed to enhance skin, hair, and overall appearance. However, with the growing demand for cosmetics and skincare products, there is an increasing concern about their safety. Many beauty products contain various chemicals, preservatives, and fragrances that can have unintended side effects on consumers, especially if they contain harmful ingredients or contaminants.

To ensure consumer safety and protect public health, cosmetic testing lab play an essential role in evaluating the safety of cosmetic products. These labs conduct comprehensive testing to identify harmful substances and contaminants that may pose risks to consumers. In this blog, we will discuss how cosmetic testing labs protect consumers by testing for harmful ingredients and contaminants, and why such testing is critical for ensuring the safety and effectiveness of beauty products.

The Importance of Cosmetic Testing Labs in Consumer Protection

Cosmetic testing labs are specialized facilities where scientific testing procedures are carried out on beauty products. These labs are designed to evaluate the safety and quality of cosmetics, ensuring that the products meet regulatory standards and are free from harmful chemicals and contaminants. This testing helps manufacturers identify and eliminate harmful ingredients before products are launched in the market, ultimately protecting consumers from adverse reactions.

When it comes to beauty products, safety is paramount. Consumers expect cosmetics to enhance their appearance without causing harm to their skin or health. In fact, some harmful ingredients can lead to allergic reactions, skin irritation, hormonal disruption, and long-term health issues. Cosmetic testing labs are essential in identifying these harmful ingredients and ensuring that only safe, effective products reach the market.

1. Identifying Harmful Chemicals in Cosmetics

Many cosmetics contain a variety of chemicals that serve different functions, such as preservatives, fragrances, and colorants. While many of these chemicals are safe for most people, some can cause adverse reactions in sensitive individuals. Cosmetic testing labs play a key role in identifying harmful ingredients that may be harmful to consumers, including:

Parabens: Used as preservatives, parabens are commonly found in cosmetics. However, studies suggest that parabens may disrupt hormones and have potential links to breast cancer. Cosmetic testing labs check for these chemicals and ensure that products meet safe usage limits.

Phthalates: These chemicals are often used in fragrances and hair care products. Phthalates have been linked to endocrine disruption and reproductive harm. Testing labs screen for phthalates to protect consumers from potential health risks.

Formaldehyde: A preservative in many cosmetics, formaldehyde is a known carcinogen. Cosmetic testing labs ensure that products do not contain unsafe levels of formaldehyde and its derivatives.

Toluene: Often found in nail polish and hair dye, toluene is a volatile solvent that can cause headaches, dizziness, and other health problems. Cosmetic testing labs detect the presence of toluene and ensure that products are free from harmful levels.

By testing for these and other harmful chemicals, cosmetic testing labs ensure that products are safe for use and do not contain harmful substances that could lead to health complications.

2. Contaminant Testing for Safety Assurance

In addition to harmful ingredients, contaminants can also pose significant risks to consumers. These contaminants can occur during manufacturing, packaging, or transportation and may lead to product spoilage, allergic reactions, or even serious infections. Cosmetic testing labs play a vital role in identifying potential contaminants and ensuring that products are free from harmful microorganisms or pollutants.

Common contaminants that cosmetic testing labs screen for include:

Microbial Contamination: Bacteria, fungi, and other microorganisms can grow in cosmetic products, especially those with high moisture content. This can lead to infections or irritation, particularly in products used around sensitive areas like the eyes or mouth. Testing labs conduct microbiological testing to detect harmful microorganisms and ensure that products are sterile and safe for use.

Heavy Metals: Heavy metals such as lead, mercury, and arsenic can be found in cosmetic products due to contamination during production. These metals are toxic and can accumulate in the body over time, leading to long-term health issues such as organ damage and neurological problems. Cosmetic testing labs screen for heavy metals to ensure that beauty products do not contain harmful levels.

Pesticides and Herbicides: Some cosmetics, especially those with plant-based ingredients, may contain trace amounts of pesticides or herbicides used during cultivation. Testing labs screen for these contaminants to ensure that products are free from harmful residues.

Environmental Contaminants: In some cases, cosmetic products may be contaminated by environmental pollutants such as dust, solvents, or industrial chemicals during the production process. Cosmetic testing labs identify and eliminate such contaminants to maintain product safety.

Through rigorous contaminant testing, cosmetic labs help to ensure that consumers are not exposed to harmful substances, preserving the integrity and safety of the products they use.

3. Microbiological Testing for Preservative Efficacy

Preservatives are an essential component of most cosmetic products, as they help extend the shelf life of beauty products and prevent the growth of harmful bacteria and mold. However, some preservatives can have negative effects on sensitive skin, causing irritation or allergic reactions. Cosmetic testing labs conduct microbiological testing to evaluate the effectiveness of preservatives and ensure that they are safe for use in beauty products.

The microbiological testing process involves inoculating a product with different types of bacteria and fungi to determine whether the preservatives in the product can effectively inhibit microbial growth. If a product fails this test, it may need to be reformulated with more effective preservatives or other methods of ensuring product safety.

Additionally, testing labs ensure that preservatives are used in the appropriate concentrations to provide maximum efficacy without causing harm to consumers. This type of testing is essential for preventing the growth of harmful microorganisms in products like moisturizers, shampoos, and face creams, which can have prolonged contact with the skin.

4. Allergen Testing for Sensitive Skin

One of the most common concerns among consumers is the potential for allergic reactions to cosmetic products. Fragrances, preservatives, colorants, and other ingredients can cause adverse reactions such as rashes, hives, and swelling in sensitive individuals. Cosmetic testing labs conduct allergen testing to identify ingredients that could trigger allergic responses.

By testing for common allergens and ensuring that cosmetic products are free from known irritants, labs help prevent allergic reactions and protect consumers' health. This testing is particularly important for products intended for sensitive areas of the body, such as the face, eyes, and lips.

5. Regulatory Compliance and Consumer Confidence

Cosmetic testing labs help ensure that products meet the safety standards set by regulatory agencies, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). These agencies require manufacturers to test their products for harmful ingredients and contaminants to ensure consumer safety. By adhering to these regulations, cosmetic brands build consumer trust and confidence, knowing that their products have been thoroughly tested for safety.

Conclusion

Cosmetic testing labs are an essential part of the beauty industry, playing a vital role in protecting consumers from harmful ingredients and contaminants. Through rigorous testing for harmful chemicals, contaminants, allergens, and preservatives, these labs ensure that beauty products meet safety standards and are safe for use. With consumer safety at the forefront, cosmetic testing labs help manufacturers create products that consumers can trust, reducing the risk of allergic reactions, skin irritation, and long-term health issues. As the demand for beauty products continues to grow, the role of cosmetic testing labs in ensuring the safety and effectiveness of these products becomes more important than ever.